Brief: Avertix To Become Publicly Traded Via Merger With Bios Acquisition Corp

BioPlus Acquisition

03/05/2023 13:57

May 3 (Reuters) - BioPlus Acquisition Corp  BIOS.O :
    * AVERTIX, MAKER OF FIRST AND ONLY FDA-APPROVED IMPLANTABLE
HEART
ATTACK WARNING SYSTEM, TO BECOME PUBLICLY TRADED VIA MERGER WITH
BIOS ACQUISITION CORPORATION
    * BIOPLUS ACQUISITION CORP - TRANSACTION VALUES AVERTIX AT
AN
ENTERPRISE VALUE OF $195 MILLION
    * BIOPLUS ACQUISITION CORP - COMBINED CO, WHICH WILL BE
NAMED
AVERTIX MEDICAL, INC. & IS EXPECTED TO BE LISTED ON NASDAQ UNDER
TICKER SYMBOL "AVRT"
    * BIOPLUS ACQUISITION CORP -  AFTER CLOSING OF TRANSACTION
BIOS'
PUBLIC SHAREHOLDERS ARE EXPECTED TO OWN ABOUT 50% OF OUTSTANDING
SHARES OF COMBINED CO
    * BIOPLUS ACQUISITION CORP -  AFTER CLOSING OF TRANSACTION
EXISTING AVERTIX SHAREHOLDERS TO OWN ABOUT 29% OF COMBINED CO

Source text for Eikon:  ID:nGNX8RjG2d 
Further company coverage:  BIOS.O 

 ((Reuters.Briefs@thomsonreuters.com;))